Please use this identifier to cite or link to this item:
http://localhost:8080/xmlui/handle/123456789/9345
Title: | Microbiological and clinical characteristics of Streptococcus pneumoniae serotype 3 infection and risk factors for severe outcome: A multicenter observational study |
Authors: | Aydin, Merve Arslan Janapatla, Rajendra Prasad Chen, Chyi-Liang Li, Hsin-Chieh Su, Lin-Hui Chiu, Cheng-Hsun |
Keywords: | Streptococcus pneumoniae Serotype 3 Mortality Prognosis Antimicrobial susceptibility Sequence type |
Issue Date: | Jun-2023 |
Publisher: | Elsevier Taiwan LLC |
Citation: | Original Article |
Abstract: | Abstract Background/purpose: Serotype 3 has persisted to be an important cause of invasive pneumococcal disease in adults in the post-vaccine era. We aimed to investigate clinical and microbiological characteristics of Streptococcus pneumoniae serotype 3 infection in Taiwan and identify the risk factors associated with severe clinical outcome. Methods: A multicenter observational study was conducted to analyze serotype 3 isolates collected between 2012 and 2021. Demographics, comorbidities, and risk categories were statistically compared with clinical outcome. Antimicrobial susceptibility testing and multilocus sequence typing were performed. Results: A total of 146 isolates were collected, including 12 isolates regarded as colonizers. Among 134 infected cases, 54 (40.3%) were aged 65 and older. Mortality was significantly associated with diabetes mellitus, immunosuppression, immunodeficiency, high-risk status, and older age. Susceptibility rates were high to levofloxacin (98.9%), moxifloxacin (100%), vancomycin (100%), and ceftriaxone (97.3%). 25.3% (37/146) of the isolates showed intermediate susceptibility and 0.7% (1/146) showed resistance to penicillin. ST180 was the dominant seq Conclusions: Serotype 3 infection showed a high mortality rate, especially in patients with older ages and comorbidities. Although the incidence rates decreased during the COVID-19 pandemic, serotype 3 remained as an important cause of infection after the implementation of PCV13. Developing a more effective vaccine against serotype 3 and monitoring the antimicrobial-resistant sequence types are necessary. |
URI: | http://localhost:8080/xmlui/handle/123456789/9345 |
Appears in Collections: | VOL 56 NO 3 2023 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
598-604.pdf | 842.85 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.